Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(33%)
Terminated
1(11%)

Phase Distribution

Ph phase_1
2
22%
Ph phase_3
4
44%
Ph not_applicable
3
33%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 3Large-scale testing
4(44.4%)
N/ANon-phased studies
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Terminated(1)
Other(3)

Detailed Status

unknown3
Recruiting3
Not yet recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (22.2%)
Phase 34 (44.4%)
N/A3 (33.3%)

Trials by Status

not_yet_recruiting222%
terminated111%
unknown333%
recruiting333%

Recent Activity

3 active trials
Showing 5 of 9
recruitingphase_3

DEB-TACE vs cTACE in HCC After TIPS

NCT07322848
not_yet_recruitingphase_1

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

NCT07522411
recruitingphase_3

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

NCT06900543
recruitingnot_applicable

SIRT Versus cTACE for Unresectable HCC (CHANCE2506)

NCT06909708
not_yet_recruitingphase_3

A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma

NCT06779461
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07322848Phase 3

DEB-TACE vs cTACE in HCC After TIPS

Recruiting
NCT07522411Phase 1

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Not Yet Recruiting
NCT06900543Phase 3

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Recruiting
NCT06909708Not Applicable

SIRT Versus cTACE for Unresectable HCC (CHANCE2506)

Recruiting
NCT06779461Phase 3

A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma

Not Yet Recruiting
NCT04635527Phase 1

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Terminated
NCT05472896Phase 3

TACE With Dicycloplatin(TP21) in Unresectable HCC

Unknown
NCT04738188Not Applicable

Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;

Unknown
NCT03969576Not Applicable

Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)

Unknown

All 9 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
9